• 1. Fe/Fe3C@C nanoparticles encapsulated in N-doped graphene–CNTs framework as an efficient bifunctional oxygen electrocatalyst for robust rechargeable Zn–air batteries?
  Zhiyan Chen,Nan Wu,Yaobing Wang,Bing Wang,Yingde Wang J. Mater. Chem. A, 2018,6, 516-526
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
• 5. Fc microparticles can modulate the physical extent and magnitude of complement activity?
  David White,Sean R. Stowell Biomater. Sci., 2017,5, 463-474

Introduction to (R)-3-Amino-3-(4-methylphenyl)propan-1-ol (CAS No. 1071436-36-6)

(R)-3-Amino-3-(4-methylphenyl)propan-1-ol, identified by its CAS number 1071436-36-6, is a significant compound in the field of chiral chemistry and pharmaceutical research. This enantiomerically pure alcohol has garnered attention due to its structural complexity and potential applications in drug development. The presence of a stereogenic center at the amino-substituted propanol backbone, combined with a bulky 4-methylphenyl group, makes this molecule a valuable candidate for exploring novel pharmacological interactions.

The compound's stereochemistry is particularly noteworthy, as the (R)-configuration often dictates specific biological activities. In recent years, there has been a growing interest in chiral drugs due to their improved efficacy and reduced side effects compared to their racemic counterparts. The synthesis of enantiomerically pure intermediates like (R)-3-Amino-3-(4-methylphenyl)propan-1-ol is crucial for developing such advanced pharmaceuticals.

Recent studies have highlighted the importance of this compound in the synthesis of protease inhibitors, which are pivotal in treating various inflammatory and infectious diseases. The 4-methylphenyl moiety enhances binding affinity to target enzymes by providing steric hindrance and hydrophobic interactions. This feature has been leveraged in the design of next-generation antiviral and anticancer agents.

In addition to its role in protease inhibition, (R)-3-Amino-3-(4-methylphenyl)propan-1-ol has shown promise in the development of central nervous system (CNS) drugs. The aromatic ring system contributes to blood-brain barrier penetration, making it an attractive scaffold for neuroactive compounds. Researchers have reported its utility in synthesizing novel ligands for GABA receptors, which are involved in anxiety and sleep disorders.

The synthesis of this compound typically involves asymmetric reduction or chiral resolution techniques. Advanced catalytic systems, such as transition metal complexes, have been employed to achieve high enantiomeric excess with minimal byproducts. These methodologies align with the green chemistry principles, emphasizing sustainability and efficiency in pharmaceutical production.

From a medicinal chemistry perspective, the structural features of (R)-3-Amino-3-(4-methylphenyl)propan-1-ol make it a versatile building block for drug discovery. Its compatibility with various functional groups allows for easy modifications, enabling the creation of diverse chemical libraries. High-throughput screening campaigns have utilized derivatives of this compound to identify potent bioactive molecules.

The pharmacokinetic properties of this compound are also under investigation. Studies indicate that the 4-methylphenyl group enhances metabolic stability while maintaining good solubility. This balance is critical for achieving optimal therapeutic levels and minimizing adverse effects. Computational modeling has been instrumental in predicting these properties before experimental validation.

Future research directions include exploring the compound's role in enzyme engineering and biosynthetic pathways. By understanding its interactions at a molecular level, scientists can develop more effective biocatalysts for industrial applications. Additionally, its potential as a chiral auxiliary in asymmetric synthesis remains an exciting area for innovation.

The commercial significance of (R)-3-Amino-3-(4-methylphenyl)propan-1-ol cannot be overstated. As demand for enantiomerically pure compounds grows, suppliers are focusing on scalable and cost-effective production methods. Collaborative efforts between academia and industry are fostering advancements that could revolutionize drug development pipelines.

In conclusion, (R)-3-Amino-3-(4-methylphenyl)propan-1-ol (CAS No. 1071436-36-6) represents a cornerstone in modern pharmaceutical research. Its unique structural attributes and broad applicability underscore its importance as both an intermediate and a lead compound. As scientific understanding evolves, this molecule will likely continue to play a pivotal role in shaping the future of medicine.

• 936499-92-2((3r)-3-amino-3-phenyl-1-propanol Hydrochloride (1:1))
• 170564-98-4((R)-3-Amino-3-phenylpropan-1-ol)
• 68208-22-0(3-m-tolyl-dl-β-alaninol)
• 82769-76-4((3S)-3-amino-3-phenylpropan-1-ol)
• 936499-93-3((3s)-3-amino-3-phenylpropan-1-ol;hydrochloride)
• 1213645-36-3((3S)-3-amino-3-(4-methylphenyl)propan-1-ol)
• 14593-04-5(3-Amino-3-phenyl-1-propanol)
• 683220-57-7(3-amino-3-(4-ethylphenyl)propan-1-ol)
• 1212834-96-2((S)-3-M-Tolyl-β-alaninol)
• 68208-23-1(3-Amino-3-(4-methylphenyl)propan-1-ol)